Soligenix enters into exclusive option agreement with silk road therapeutics for rights to topical pentoxifylline designed to treat behÇet's disease

Phase 2/3-ready orphan disease program complements company's existing late-stage rare disease pipeline princeton, n.j. , may 1, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it has entered into an exclusive option agreement with silk road therapeutics, a privately-held company.
SNGX Ratings Summary
SNGX Quant Ranking